SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0000950170-24-052165
Filing Date
2024-05-02
Accepted
2024-05-02 16:24:20
Documents
103
Period of Report
2024-03-31

Document Format Files

Seq Description Document Type Size
1 10-Q bbio-20240331.htm   iXBRL 10-Q 2989902
2 EX-10.2 bbio-ex10_2.htm EX-10.2 2030657
3 EX-10.3 bbio-ex10_3.htm EX-10.3 200680
4 EX-10.4 bbio-ex10_4.htm EX-10.4 931156
5 EX-10.5 bbio-ex10_5.htm EX-10.5 879950
6 EX-10.6 bbio-ex10_6.htm EX-10.6 22585
7 EX-10.7 bbio-ex10_7.htm EX-10.7 16648
8 EX-31.1 bbio-ex31_1.htm EX-31.1 24713
9 EX-31.2 bbio-ex31_2.htm EX-31.2 24833
10 EX-32.1 bbio-ex32_1.htm EX-32.1 11371
11 EX-32.2 bbio-ex32_2.htm EX-32.2 11635
  Complete submission text file 0000950170-24-052165.txt   19757972

Data Files

Seq Description Document Type Size
12 XBRL TAXONOMY EXTENSION SCHEMA WITH EMBEDDED LINKBASES DOCUMENT bbio-20240331.xsd EX-101.SCH 2611017
107 EXTRACTED XBRL INSTANCE DOCUMENT bbio-20240331_htm.xml XML 2771197
Mailing Address 3160 PORTER DR. SUITE 250 PALO ALTO CA 94304
Business Address 3160 PORTER DR. SUITE 250 PALO ALTO CA 94304 (650) 391-9740
BridgeBio Pharma, Inc. (Filer) CIK: 0001743881 (see all company filings)

IRS No.: 000000000 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 10-Q | Act: 34 | File No.: 001-38959 | Film No.: 24908753
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)